Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — BIO-Europe 2026
17 slides from Avecho Biotechnology's conference presentation, Nov 16, 2026
Slide 1: Avecho presents at BIO-Europe – Europe's largest biopharmaceutical partnering event
ASX Announcement 16 November 2026 For personal use only Avecho presents at BIO-Europe – Europe’s largest biopharmaceutical partnering event Key Highlights • CEO Dr Paul Gavin presented Avecho at BIO-Europe 2026 in Cologne, Germany (9–11 November 2026), one of the largest international biopharmaceuti
Slide 2: About Avecho
About Avecho Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM is derived from Vitamin E using unique, proprietary and patented processes and is proven to enh
Slide 3: For personal use only
looking statements speak only as at the date of this announcement. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ ma
Slide 4: BIO-Europe 2026: Developing the first pharmaceutical cannabidiol product for insomnia
BIO-Europe 2026 Cologne, 9–11 November rsonal use only Developing the first pharmaceutical cannabidiol product for insomnia www.avecho.com.au | ASX:AVE
Slide 5: Safe Harbour Statement
This presentation, and any differences may be material representations made before, during (whether positive or negative). or after the presentation, may The risks that may cause Avecho‘s Safe Harbour include forward-looking statements actual results, performance or rsonal use only that are inherent
Slide 6: Company snapshot: Where Avecho sits today
COMPANY SNAPSHOT Where Avecho sits today rsonal use only Proprietary product TPM-enhanced synthetic cannabidiol (CBD) capsule; IP protection to ~2043. A registered pharmaceutical, not a medicinal-cannabis product. Partnered for Australia Large, growing indication >850 million adults with clinically
Slide 7: Insomnia is a major problem worldwide
Insomnia is a major ~1 in 3 rsonal use only adults report insomnia problem worldwide symptoms² Broadly defined as difficulty initiating or maintaining sleep Lost productivity, US alone Insomnia can be a symptom of a range of other $US 207bn disorders, particularly mental health and psychiatric per y
Slide 8: Pharmaceutical cannabidiol is valuable
Pharmaceutical cannabidiol is valuable Cannabidiol (CBD) is the major non-psychoactive component rsonal use only of medicinal cannabis Only one pharmaceutical CBD product is approved by the FDA (Epidiolex®)1 • Epidiolex was developed by GW Pharma • Approved for rare childhood epilepsy conditions2 –
Slide 9: Avecho's TPM increases CBD absorption
Avecho’s TPM increases CBD absorption TPM increases rsonal use only TPM increases oral CBD absorption CBD Solubility Increased CBD Solubility… • Avecho developed CBD TPM capsule • Pharmaceutically preferred dosage form • Increased absorption With TPM Without TPM • GMP manufacture – stable for 3 year
Slide 10: Pivotal Phase III built to deliver a clinical signal
Pivotal Phase III built to deliver a clinical signal Day 1 Week 4 Week 8 2 1 Screening 150 mg CBD TPM Primary rsonal use only readout • Adults ≥18 years • DSM-5 insomnia R 75 mg CBD TPM ISI disorder or • ISI ≥15 Sleep efficiency N = 519 Placebo 8 weeks, double-blind, once daily 1:1:1 3 Interim analy
Slide 11: Pivotal Phase III passed its interim analysis
THE DE-RISKING EVENT Pivotal Phase III passed its interim analysis rsonal use only What the independent DMB could recommend at n = 244 0 Stop No worthwhile effect: futility Continue, but enlarge Effect smaller than assumed: more patients needed serious adverse events across all 244 participants dose
Slide 12: Hypnotic-range efficacy, minus the liabilities
EMERGING PRODUCT PROFILE Hypnotic-range efficacy, minus the liabilities Prescription hypnotics, incl. orexin rsonal use only CBD-TPM target profile antagonists Powered on an approved-hypnotic assumption; Efficacy Established interim tracking at least in line Serious adverse events A recognised class
Slide 13: A neuropsychiatric molecule, starting with sleep
BEYOND INSOMNIA A neuropsychiatric molecule, starting with sleep rsonal use only 01 02 03 Insomnia and anxiety travel CBD is now approved for Anxiety is measured in our together anxiety Phase III In a US cohort of 1 million adults, anxiety July 2026: India’s CDSCO approved a Anxiety (Beck Anxiety In
Slide 14: Growth markets: insomnia and neuropsychiatry
COMMERCIAL OPPORTUNITY Growth markets: insomnia and neuropsychiatry rsonal use only Insomnia drug market by class, US$bn¹ QUVIVIQ, the newest orexin antagonist: US$4.1bn → US$6.8bn by 2035, ~5% a year. Orexin antagonists: 2.2x sales CHF 61m → 134m in 2025² ~11% a year. 2025 2035F J&J acquires Intra-
Slide 15: Layered protection around a known molecule
INTELLECTUAL PROPERTY AND SUPPLY Layered protection around a known molecule rsonal use only CBD itself is not patentable. A well-characterised active with a known safety profile, sourced as The molecule pharmaceutical-grade synthetic API. Proprietary excipient technology, manufactured and supplied b
Slide 16: The right partnership, territory by territory
PARTNERING The right partnership, territory by territory rsonal use only What Avecho brings What we build together What the partner brings • A pivotal Phase III, completed by • The registration package for your • Regulatory leadership to register a Avecho territory new medicine locally • Finished-pr
Slide 17: Let's talk partnering
Let’s talk rsonal use only partnering Dr Paul Gavin Melbourne Office Chief Executive Officer Unit A8, 2A Westall Road T. +61 3 9002 5000 Hallmarc Business Park E. pgavin@avecho.com.au Clayton VIC 3168 Australia T: +61 3 9002 5000 E: info@avecho.com.au